



Supplementary Figure 6: B-I09 and ACY1215 combination is well tolerated. (A) Bliss combination analysis in *ARID1A*-mutated TOV21G cells to assess the synergy between the IRE1 α inhibitor B-I09 and the HDAC6 inhibitor ACY1215 *in vitro* determined by CellTiter-Glo. (B) *ARID1A* knockout RMG1 cells or TOV21G were treated with or without HDAC6 inhibitor ACY1215 (3 μ M) for 72 hours. Expression of XBP1s and a loading control β -actin was examined by immunoblot. (C) Body weight of tumor bearing mice were measured at the indicated time points during treatment in the indicated groups in the genetic *Arid1a*^{-/-}/*Pik3ca*^{H1047R} OCCC mouse model (n = 5 mice per group). (D) H&E staining of liver and kidney sections from mice of the indicated treatment groups. Scale bars = 100 μ M. Error bars represent mean with SD.